THERMAL SCIENCE

International Scientific Journal

Authors of this Paper

External Links

Yixin Peng

,

Xingsheng Yang

MOLECULAR CLASSIFICATION GUIDES FOR THE POSTOPERATIVE ADJUVANT THERAPY OF EARLY-STAGE ENDOMETRIAL CARCINOMA

ABSTRACT
Surgical treatment has been widely used for early-stage endometrial carcinoma patients, but 15-20% of patients had a poor prognosis, requiring a postoperative adjuvant therapy. With the development of molecular classification of endometrial carcinoma, the combination of molecular and clinicopathological factors can guide the prognosis risk assessment and make the adjuvant therapy selection more accurate, as a result, the survival outcome of patients can be greatly improved. In this article, the molecular classification of endometrial carcinoma is reviewed, and its guidance to the postoperative adjuvant therapy for early-stage endometrial carcinoma is discussed. It concludes that the molecular classification opens up the opportunity of creating new ideas for adjuvant treatment strategies for early endometrial cancer.
KEYWORDS
endometrial carcinoma, adjuvant therapy, molecular classification
PAPER SUBMITTED: 2023-03-16
PAPER REVISED: 2023-05-21
PAPER ACCEPTED: 2023-05-21
PUBLISHED ONLINE: 2024-05-18
DOI REFERENCE: https://doi.org/10.2298/TSCI2403217P
CITATION EXPORT: view in browser or download as text file
THERMAL SCIENCE YEAR 2024, VOLUME 28, ISSUE Issue 3, PAGES [2217 - 2224]
REFERENCES
  1. Getz, G., et al., Integrated Genomic Characterization of Endometrial Carcinoma, Nature, 497 (2013), May, pp. 67-73
  2. Oaknin, A., et al., Endometrial caNcer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up, Annals of Oncology, 33 (2022), 9, pp. 860-877
  3. Concin, N., et al., ESGO/ESTRO/ESP Guidelines for the Management of patIents with Endometrial Carcinoma，Virchows Archiv, 478 (2021), 2, pp. 153-190
  4. Prueksaritanond, N., Chantape, W., Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital, J. Med. Assoc. Thai., 99 (2016), Suppl. 2, pp. S75-S83
  5. Schultheis, A. M., et al., TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers, Int J Gynecol Pathol, 35 (2016), 4, pp. 289-300
  6. Kommoss, S., et al., Final Validation of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-Based Case Series, Ann Oncol, 29 (2018), 5, pp. 1180-1188
  7. Stelloo, E., et al., Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts, Clin. Cancer Res., 22 (2016), 16, pp. 4215-24
  8. Leon-Castillo, A., et al., Clinicopathological and Molecular Characterisation of 'Multiple-Classifier' Endometrial Carcinomas, J. Pathol., 250 (2020), 3, pp. 312-322
  9. ***, WHO Classification of Tumours Editorial Board, WHO Classification of Tumours: Female Genital Tumours, 5thed Lyon: IARC Publications, 2020, pp. 252-267
  10. Abu-Rustum, N., et al., Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Canc. Netw., 21 (2023), 2, pp. 181-209
  11. van Gool, I. C., et al., Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues, Clin. Cancer Res., 24 (2018), 13, pp. 3197-3203
  12. Mcalpine, J. N., et al., Evaluation of Treatment Effects in Patients with Endometrial Cancer and POLE Mutations: An Individual Patient Data Meta-Analysis, Cancer, 127 (2021), 14, pp. 2409-2422
  13. Jamieson, A., et al., The Emerging Role of Molecular Pathology in Directing the Systemic Treatment of Endometrial Cancer, Ther. Adv. Med. Oncol., 13 (2021), 13, 17588359211035959
  14. Eggink, F. A., et al., Immunological Profiling of Molecularly Classified High-Risk Endometrial Cancers Identifies POLE-Mutant and Microsatellite Unstable Carcinomas as Candidates for Checkpoint Inhibition, Oncoimmunology, 6 (2017), 2, e1264565
  15. Reijnen, C., et al., Mismatch Repair Deficiency as a Predictive Marker for Response to Adjuvant Radiotherapy in Endometrial Cancer, Gynecol. Oncol., 154 (2019), 1, pp. 124-130
  16. Leon-Castillo, A., et al., Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy, J. Clin. Oncol., 38 (2020), 29, pp. 3388-3397
  17. Van den Heerik, A., et al., PORTEC-4a: International Randomized Trial of Molecular Profile-Based Adjuvant Treatment for Women with High-Intermediate Risk Endometrial Cancer, Int. J. Gynecol. Cancer, 30 (2020), 12, pp. 2002-2007
  18. Kurnit, K. C., et al., CTNNB1 (Beta-Catenin) Mutation Identifies Low Grade, Early Stage Endometrial Cancer Patients at Increased Risk of Recurrence, Mod. Pathol., 30 (2017), 7, pp. 1032-1041
  19. Ravaggi, A., et al., Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma, Cancers (Basel), 14 (2022), 21, 5429
  20. Sengal, A. T., et al., FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes, Clin. Cancer. Res., 26 (2020), 17, pp. 4569-4580
  21. de Jonge, M. M., et al., Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas, Clin. Cancer Res., 25 (2019), 3, pp. 1087-1097
  22. Fader, A. N., et al., Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Over-express Her2/Neu (NCT01367002): Updated Overall Survival Analysis, Clin. Cancer Res., 26 (2020), 15, pp. 3928-3935
  23. Erickson, B. K., et al., Human Epidermal Growth Factor 2 (HER2) in Early Stage Uterine Serous Carcinoma: A Multi-Institutional Cohort Study, Gynecol. Oncol., 159 (2020), 1, pp. 17-22
  24. Vermij, L., et al., HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes, Cancers (Basel), 13 (2020), 1, 13010044
  25. Horeweg, N., et al., Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer, Cancer Immunol. Res., 8 (2020), 12, pp. 1508-1519
PDF VERSION [DOWNLOAD]
Molecular classification guides for the postoperative adjuvant therapy of early-stage endometrial carcinoma

© 2024 Society of Thermal Engineers of Serbia. Published by the Vinča Institute of Nuclear Sciences, National Institute of the Republic of Serbia, Belgrade, Serbia. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International licence